Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Agomelatine and Tropisetron — mechanism, side effects, legal status, and pricing.
Agomelatine is a non-peptide small-molecule naphthalene derivative and melatonin analog that acts as an agonist at MT1/MT2 melatonin receptors and antagonist at serotonin 5-HT2C receptors. It is an EMA-approved prescription antidepressant (Valdoxan, approved February 2009 for major depressive disorder in adults) but is NOT FDA-approved in the United States. Post-marketing surveillance identified hepatotoxicity as an important risk, prompting mandatory liver function monitoring and contraindications in hepatic impairment. Despite its prescription status, agomelatine is sold by gray-market vendors as bulk powder labeled 'for research use only.'
Tropisetron is a non-peptide small-molecule indole-tropane carboxylate ester with dual receptor activity: competitive antagonism at 5-HT3 serotonin receptors and partial agonism at α7 nicotinic acetylcholine receptors. Approved in 1992 as a prescription antiemetic (marketed as Navoban outside the United States) for chemotherapy- and radiotherapy-induced nausea and vomiting, it is NOT approved or marketed in the US. Beyond its approved indication, tropisetron has registered human RCT data in fibromyalgia and schizophrenia-associated cognitive deficits; NO validated human dosing exists for cognitive enhancement in healthy individuals. Available from gray-market research-chemical vendors labeled for laboratory research only.
Agomelatine
Tropisetron
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Agomelatine
Tropisetron
COA corpus from Disclosed Labs — independently tested batches only.
Agomelatine
1
COAs
99.9%
Avg purity
1
Labs
Tropisetron
1
COAs
99.8%
Avg purity
1
Labs
Agomelatine is an EMA-approved prescription drug for major depressive disorder in adults (approved February 2009, marketed as Valdoxan/Melitor/Thymanax), not an unstudied novel compound. It is NOT FDA-approved in the United States despite completed clinical trials. Pooled human trial data identified hepatotoxicity as an important risk: transaminase elevations >3× upper limit of normal occurred in 1.34% of patients on 25 mg/day and 2.51% on 50 mg/day versus placebo, mostly hepatocellular and idiosyncratic. In rodent studies, chronic agomelatine administration induced regional increases in hippocampal neurogenesis (rat dentate gyrus), normalized stress-suppressed hippocampal neuronal activity and reversed stress-induced decreases in doublecortin expression in chronically stressed rats, and ameliorated stress-induced memory deficits in a mouse chronic social defeat stress model.
Tropisetron is an approved prescription drug for chemotherapy-/radiotherapy-induced nausea and vomiting. Human RCT data exist for two investigational uses: (a) a randomized, double-blind, placebo-controlled multicenter trial in 418 fibromyalgia patients (5/10/15 mg once daily × 10 days) reported a higher responder rate in the 5 mg arm than placebo; and (b) an 8-week randomized, double-blind, placebo-controlled trial in 40 risperidone-treated schizophrenia patients (10 mg/day add-on) improved P50 auditory gating and sustained visual attention versus placebo. NO validated human dosing exists for cognitive enhancement in healthy individuals. Preclinical findings include: in vitro (Xenopus oocytes) confirmation of α7-selective partial agonism; in vivo (young/aged rats, aged rhesus monkeys) improvements in novel-object-recognition and delayed-match-to-sample accuracy with systemic tropisetron; rat 3-nitropropionic-acid Huntington's model showing improved motor/behavioral deficits and modulation of Nrf2/HO-1, PI3K/Akt, and JAK2/NF-κB signaling; and rat pilocarpine temporal-lobe-epilepsy model demonstrating reduced spontaneous seizures and hippocampal sclerosis via an α7nAChR-dependent (alpha-bungarotoxin-reversible) mechanism.
Agomelatine and Tropisetron are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs